Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer

Summary

The study was conducted on patients with advanced right-sided colon cancer, and the clinical pathological and prognostic data of the patients were compared between the two groups of patients who were randomly divided into those undergoing SMV and SMA left resection, with the aim of resolving the controversy over the left resection boundary of CME/D3 lymph node dissection through this study, and to clarify whether SMA left resection is superior to SMV left resection.

Conditions

• Colon Cancer

Interventions

PROCEDURE

SMA lymph node dissection

The lymph node dissection boundary is on the left side of the superior mesenteric artery (SMA)

PROCEDURE

SMV lymph node dissection

The lymph node dissection boundary is on the left side of the superior mesenteric vein (SMV)

Sponsors & Collaborators

• Jiangxi Provincial Cancer Hospital

  collaborator OTHER

• Jiangsu Cancer Institute & Hospital

  collaborator OTHER

• Liaoning Cancer Hospital & Institute

  collaborator OTHER

• The First Affiliated Hospital of Soochow University

  collaborator OTHER

• Shanxi Province Cancer Hospital

  collaborator OTHER

• The First Affiliated Hospital of Shanxi Medical University

  collaborator OTHER

• Shaoxing People's Hospital

  collaborator OTHER

• Shaoxing Second Hospital

  collaborator OTHER

• Ningbo No. 1 Hospital

  collaborator OTHER

• Ningbo No.2 Hospital

  collaborator OTHER

• Jinhua Central Hospital

  collaborator OTHER

• Affiliated Hospital of Jiaxing University

  collaborator OTHER

• The First People's Hospital of Huzhou

  collaborator OTHER

• The Central Hospital of Lishui City

  collaborator OTHER

• Lishui Country People's Hospital

  collaborator OTHER

• Zhejiang University

  collaborator OTHER

• Yuyao People's Hospital

  collaborator OTHER

• The Third Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• First Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• Cancer Hospital of Guangxi Medical University

  collaborator OTHER

• Ningbo Medical Center Lihuili Hospital

  collaborator OTHER_GOV

• Ruijin Hospital

  collaborator OTHER

• Second Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• First Affiliated Hospital of Zhejiang University

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  collaborator OTHER

• Shanghai Cancer Hospital, China

  collaborator OTHER

• The Affiliated Tumor Hospital of Harbin Medical University

  collaborator UNKNOWN

• Shanghai 10th People's Hospital

  collaborator OTHER

• The Second Affiliated Hospital of Harbin Medical University

  collaborator OTHER

• Xiangshan No.1 People' s Hospital

  collaborator UNKNOWN

• Zhejiang Province People's Hospital

  collaborator UNKNOWN

• Sir Run Run Shaw Hospital

  collaborator OTHER

• Sun Yat-sen University Cancer Hosptial

  collaborator UNKNOWN

• Haixing Ju, MD

  lead OTHER

Principal Investigators

• Haixing Ju · Zhejiang Cancer Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

78 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-07-01

Primary Completion

2027-06-30

Completion

2032-06-30

Countries

• China

Study Locations